Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
J Neurosci. 2011 May 4;31(18):6627-38. doi: 10.1523/JNEUROSCI.0203-11.2011.
In Alzheimer's disease (AD), dementia severity correlates strongly with decreased synapse density in hippocampus and cortex. Numerous studies report that hippocampal long-term potentiation (LTP) can be inhibited by soluble oligomers of amyloid β-protein (Aβ), but the synaptic elements that mediate this effect remain unclear. We examined field EPSPs and whole-cell recordings in wild-type mouse hippocampal slices. Soluble Aβ oligomers from three distinct sources (cultured cells, AD cortex, or synthetic peptide) inhibited LTP, and this was prevented by the selective NR2B inhibitors ifenprodil and Ro 25-6981. Soluble Aβ enhanced NR2B-mediated NMDA currents and extrasynaptic responses; these effects were mimicked by the glutamate reuptake inhibitor dl-threo-β-benzyloxyaspartic acid. Downstream, an Aβ-mediated rise in p38 mitogen-activated protein kinase (MAPK) activation was followed by downregulation of cAMP response element-binding protein, and LTP impairment was prevented by inhibitors of p38 MAPK or calpain. Thus, soluble Aβ oligomers at low nanomolar levels present in AD brain increase activation of extrasynaptic NR2B-containing receptors, thereby impairing synaptic plasticity.
在阿尔茨海默病(AD)中,痴呆症的严重程度与海马体和皮质中突触密度的降低密切相关。许多研究报告称,淀粉样β蛋白(Aβ)的可溶性寡聚体可以抑制海马长时程增强(LTP),但介导这种效应的突触元件仍不清楚。我们在野生型小鼠海马切片中检查了场 EPSP 和全细胞记录。来自三种不同来源(培养细胞、AD 皮质或合成肽)的可溶性 Aβ 寡聚体抑制了 LTP,如果尼地平和 Ro 25-6981 等选择性 NR2B 抑制剂存在,这种抑制作用就会被阻止。可溶性 Aβ 增强了 NR2B 介导的 NMDA 电流和突触外反应;谷氨酸再摄取抑制剂 dl-threo-β-苯甲酰氧基天冬氨酸模拟了这些作用。在下游,Aβ 介导的 p38 丝裂原活化蛋白激酶(MAPK)激活增加,随后 cAMP 反应元件结合蛋白下调,p38 MAPK 或钙蛋白酶抑制剂可预防 LTP 损伤。因此,AD 大脑中存在的低纳摩尔水平的可溶性 Aβ 寡聚体增加了突触外含有 NR2B 的受体的激活,从而损害了突触可塑性。